Strategy & techno-economic consulting

A genuinely thin, generic-professional-service category — dedicated bioprocess scale-up and technology-transfer consulting, distinct from CDMOs that manufacture rather than advise — one confirmed dedicated consultancy as of 2026.

Consultancies and data platforms that value biotechnology and pharmaceutical patent portfolios for licensing negotiations, M&A, litigation and capital raises — translating a patent estate covering therapeutics, diagnostics or platform technologies into a defensible monetary figure.

Advanced process simulation and financial modeling services that determine the commercial viability, optimal facility sizing, and Cost of Goods Sold (COGS) for emerging biomanufacturing technologies before capital is deployed.